728 related articles for article (PubMed ID: 23187605)
1. Atypical hemolytic uremic syndrome (aHUS): making the diagnosis.
Laurence J
Clin Adv Hematol Oncol; 2012 Oct; 10(10 Suppl 17):1-12. PubMed ID: 23187605
[TBL] [Abstract][Full Text] [Related]
2. Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis.
Laurence J; Haller H; Mannucci PM; Nangaku M; Praga M; Rodriguez de Cordoba S
Clin Adv Hematol Oncol; 2016 Nov; 14 Suppl 11(11):2-15. PubMed ID: 27930620
[TBL] [Abstract][Full Text] [Related]
3. Thrombotic microangiopathies: thrombotic thrombocytopenic purpura / hemolytic uremic syndrome.
Polito MG; Kirsztajn GM
J Bras Nefrol; 2010; 32(3):303-15. PubMed ID: 21103695
[TBL] [Abstract][Full Text] [Related]
4. Natural history of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
Wada H; Matsumoto T; Yamashita Y
Semin Thromb Hemost; 2014 Nov; 40(8):866-73. PubMed ID: 25377323
[TBL] [Abstract][Full Text] [Related]
5. Complement activation in diseases presenting with thrombotic microangiopathy.
Meri S
Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
[TBL] [Abstract][Full Text] [Related]
6. [Diagnosis and treatment of TMA based on Japanese clinical guides].
Wada H; Hasegawa K; Watanabe M
Rinsho Ketsueki; 2017; 58(7):849-856. PubMed ID: 28781284
[TBL] [Abstract][Full Text] [Related]
7. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand.
Fox LC; Cohney SJ; Kausman JY; Shortt J; Hughes PD; Wood EM; Isbel NM; de Malmanche T; Durkan A; Hissaria P; Blombery P; Barbour TD
Nephrology (Carlton); 2018 Jun; 23(6):507-517. PubMed ID: 29419916
[TBL] [Abstract][Full Text] [Related]
8. Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopathies.
Cataland SR; Wu HM
Eur J Intern Med; 2013 Sep; 24(6):486-91. PubMed ID: 23739653
[TBL] [Abstract][Full Text] [Related]
9. [Diagnosis and management of thrombotic microangiopathies].
Matsumoto M
Rinsho Ketsueki; 2015 Oct; 56(10):2092-9. PubMed ID: 26458449
[TBL] [Abstract][Full Text] [Related]
10. Pathology Consultation on the Diagnosis and Treatment of Thrombotic Microangiopathies (TMAs).
Williams LA; Marques MB;
Am J Clin Pathol; 2016 Feb; 145(2):158-65. PubMed ID: 27124904
[TBL] [Abstract][Full Text] [Related]
11. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand.
Fox LC; Cohney SJ; Kausman JY; Shortt J; Hughes PD; Wood EM; Isbel NM; de Malmanche T; Durkan A; Hissaria P; Blombery P; Barbour TD
Intern Med J; 2018 Jun; 48(6):624-636. PubMed ID: 29582550
[TBL] [Abstract][Full Text] [Related]
12. The Differential Diagnosis and Treatment of Thrombotic Microangiopathies.
Bommer M; Wölfle-Guter M; Bohl S; Kuchenbauer F
Dtsch Arztebl Int; 2018 May; 115(19):327-334. PubMed ID: 29875054
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and management of complement mediated thrombotic microangiopathies.
Cataland SR; Wu HM
Blood Rev; 2014 Mar; 28(2):67-74. PubMed ID: 24534133
[TBL] [Abstract][Full Text] [Related]
14. Thrombotic microangiopathy in malignant hypertension and hemolytic uremic syndrome (HUS)/ thrombotic thrombocytopenic purpura (TTP): can we differentiate one from the other?
Shibagaki Y; Fujita T
Hypertens Res; 2005 Jan; 28(1):89-95. PubMed ID: 15969259
[TBL] [Abstract][Full Text] [Related]
15. The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring.
Mannucci PM; Cugno M
Thromb Res; 2015 Nov; 136(5):851-4. PubMed ID: 26386489
[TBL] [Abstract][Full Text] [Related]
16. [Hemolytic and uremic syndrome and related thrombotic microangiopathies: Epidemiology, pathophysiology and clinics].
Rafat C; Coppo P; Fakhouri F; Frémeaux-Bacchi V; Loirat C; Zuber J; Rondeau E
Rev Med Interne; 2017 Dec; 38(12):817-824. PubMed ID: 28711159
[TBL] [Abstract][Full Text] [Related]
17. Microangiopathic Hemolytic Anemia in Pregnancy.
Neave L; Scully M
Transfus Med Rev; 2018 Oct; 32(4):230-236. PubMed ID: 30177429
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP.
Cataland SR; Holers VM; Geyer S; Yang S; Wu HM
Blood; 2014 Jun; 123(24):3733-8. PubMed ID: 24695849
[TBL] [Abstract][Full Text] [Related]
19. The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry.
Hassan S; Westwood JP; Ellis D; Laing C; Mc Guckin S; Benjamin S; Scully M
Br J Haematol; 2015 Dec; 171(5):830-5. PubMed ID: 26359646
[TBL] [Abstract][Full Text] [Related]
20. Atypical reduction of plasma ADAMTS13 activity by a non-IgG-type inhibitor in a patient with hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli.
Nakayama S; Hirashio S; Yorishima H; Doi T; Yoshida Y; Matsumoto M; Masaki T
CEN Case Rep; 2019 Nov; 8(4):266-270. PubMed ID: 31177384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
